Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable Securities

Marketable Securities

6 Months Ended

Jun. 30, 2023

Investments, Debt and Equity Securities [Abstract]

Marketable securities consisted of the following as of June 30, 2023:


June 30, 2023	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Marketable securities, available-for-sale:
U.S. Treasury obligations	$	19,031,622	$	—	$	(1,714	)	$	19,029,908
Total	$	19,031,622	$	—	$	(1,714	)	$	19,029,908


December 31, 2022	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Marketable securities, available-for-sale:
U.S. Treasury obligations	$	15,756,902	$	104,718	$	—	$	15,861,620
Total	$	15,756,902	$	104,718	$	—	$	15,861,620

As of June 30, 2023, the Company held five U.S. Treasury debt securities that were in an unrealized loss position totaling $1,714. As of December 31, 2022, the Company held three U.S. Treasury debt securities that were in an unrealized gain position totaling $104,718.

The Company received proceeds of $15.4 million from maturities of marketable securities for the period ended June 30, 2023. The Company received proceeds of $4.96 million from maturities of marketable securities for the year ended December 31, 2022. The Company did not realize any gains or losses from maturities of marketable securities for the period ended June 30, 2023 or the year ended December 31, 2022.